| Autor: |
An J; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Liu Y; school of public health, Gansu University Of Chinese Medicine, Lanzhou, China., Ma Y; Inspection and testing, Gansu Medical Device Inspection And Testing Institute, Lanzhou, China., Jiao YZ; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Liang XF; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Jin N; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Bao J; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Jiang N; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China., Zhang XS; Immunization Planning Department, Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.; school of public health, Gansu University Of Chinese Medicine, Lanzhou, China. |
| Abstrakt: |
To investigate the HPV vaccine coverage and post-vaccination adverse reactions in Gansu Province, Western China, from 2018 to 2021. Data on suspected adverse reactions to HPV vaccines were collected from the Chinese Vaccine Adverse Event Following Immunization (AEFI). Estimate the incidence rates of Common Adverse Reaction and Rare Adverse Reaction. HPV vaccine coverage among females in different age groups was calculated using data from the Gansu Provincial Immunization Information Platform. The first-dose HPV vaccine coverage rate among females aged 9 to 45 was 2.02%, with the lowest rate of less than 1% observed in females aged 9 to 14. From 2018 to 2021, the incidence rates of Common Adverse Reaction and Rare Adverse Reaction reported in females after HPV vaccination were 11.82 and 0.39 per 100,000 doses, respectively. Common Adverse Reaction included fever (5.52 per 100,000 doses), local redness and swelling (3.33 per 100,000 doses), fatigue (3.15 per 100,000 doses), headache (2.76 per 100,000 doses), as well as local induration and nausea/vomiting (1.97 per 100,000 doses). Adverse reactions mainly occurred within 1 day after vaccination, followed by 1 to 3 days after vaccination. The HPV vaccine coverage rate among females aged 9 to 14 in Gansu Province is remarkably low, and there is an urgent need to enhance vaccine coverage. From 2018 to 2021, the incidence of Adverse reaction Following Immunization HPV vaccination fell within the expected range, indicating the vaccine's safety profile. |
